Atıf İçin Kopyala
GÜMÜŞ M., Bilici A., Odabas H., Ustaalioglu B. B. O., Kandemir N., Demirci U., ...Daha Fazla
WORLD JOURNAL OF UROLOGY, cilt.35, sa.7, ss.1103-1110, 2017 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
35
Sayı:
7
-
Basım Tarihi:
2017
-
Doi Numarası:
10.1007/s00345-016-1964-6
-
Dergi Adı:
WORLD JOURNAL OF UROLOGY
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Sayfa Sayıları:
ss.1103-1110
-
Anahtar Kelimeler:
Stage I, Nonseminomatous germ cell tumor, Testicular cancer, Chemotherapy, Surveillance, LYMPH-NODE DISSECTION, TERM-FOLLOW-UP, CISPLATIN CHEMOTHERAPY, TESTIS CANCER, RISK, BLEOMYCIN, ETOPOSIDE, MANAGEMENT, TRIAL
-
Gazi Üniversitesi Adresli:
Evet
Özet
Background Currently, it is accepted that risk assessment of clinical stage I (CS I) nonseminomatous germ cell tumors (NSGCT) patient is mainly dependent on the presence of lymphovascular invasion (LVI). Initial active surveillance, adjuvant chemotherapy and retroperitoneal lymph node dissection (RPLND) are acceptable treatment options for these patients, but there is no uniform consensus. The purpose of this study was to compare outcomes of active surveillance with adjuvant chemotherapy.